• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 4. Exfoliation of transition-metal dichalcogenides using ATP in aqueous solution?
  Xinyi Liu,Huan Chen,Jing Lin,Yi Li,Liangqia Guo Chem. Commun., 2019,55, 2972-2975
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolecarboxamides and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolecarboxylic acids and derivatives Indolecarboxamides and derivatives

Recent Advances in the Study of N,N-dimethyl-1H-indole-3-carboxamide (CAS: 27409-13-8): A Comprehensive Research Brief

N,N-dimethyl-1H-indole-3-carboxamide (CAS: 27409-13-8) has recently emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This indole derivative has shown promising potential in various therapeutic applications, particularly in the modulation of biological pathways related to inflammation, oncology, and neurological disorders. The compound's unique structural features, including the presence of a dimethylamino group and an indole core, contribute to its diverse pharmacological activities. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its therapeutic efficacy in preclinical models.

One of the key areas of research has been the compound's role as a modulator of protein-protein interactions (PPIs). A 2023 study published in the Journal of Medicinal Chemistry demonstrated that N,N-dimethyl-1H-indole-3-carboxamide exhibits high affinity for specific binding sites on transcription factors involved in inflammatory responses. The study utilized X-ray crystallography and molecular docking simulations to reveal the compound's binding mode, providing valuable insights for the design of more potent analogs. Additionally, the compound's ability to cross the blood-brain barrier has sparked interest in its potential applications for neurodegenerative diseases, such as Alzheimer's and Parkinson's.

In the context of synthetic chemistry, recent advancements have been made in the scalable production of N,N-dimethyl-1H-indole-3-carboxamide. A team of researchers from the University of Cambridge reported a novel catalytic method for the efficient N-dimethylation of indole-3-carboxamide, significantly reducing the use of hazardous reagents and improving overall yield (Chemical Communications, 2023). This development is particularly relevant for industrial-scale production, as it addresses previous challenges related to cost and environmental impact. Furthermore, the compound's stability under physiological conditions has been confirmed through pharmacokinetic studies, highlighting its suitability for further drug development.

The anticancer potential of N,N-dimethyl-1H-indole-3-carboxamide has also been a focal point of recent investigations. In vitro and in vivo studies have shown that the compound induces apoptosis in several cancer cell lines, including breast, lung, and colorectal cancers. A 2024 study in Cancer Research revealed that the compound's mechanism involves the inhibition of key signaling pathways, such as the PI3K/AKT/mTOR cascade, which are often dysregulated in malignancies. These findings suggest that N,N-dimethyl-1H-indole-3-carboxamide could serve as a lead compound for the development of targeted cancer therapies, particularly in cases where resistance to conventional treatments is observed.

Despite these promising developments, challenges remain in the clinical translation of N,N-dimethyl-1H-indole-3-carboxamide. Issues such as bioavailability, potential off-target effects, and long-term toxicity require further investigation. Ongoing research is exploring structural modifications to enhance the compound's selectivity and pharmacokinetic profile. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical applications. As the body of evidence grows, N,N-dimethyl-1H-indole-3-carboxamide continues to hold significant promise as a versatile scaffold for drug discovery in multiple therapeutic areas.

• 61788-25-8(1h-indole-3-carboxylic acid benzylamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)